这篇文章不错，转发给_老虎社区_美港股上老虎

edward28
2021-03-05

这篇文章不错，转发给大家看

Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst

Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding

Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":367050139,"tweetId":"367050139","gmtCreate":1614896392221,"gmtModify":1703482616960,"author":{"id":3540880674211350,"idStr":"3540880674211350","authorId":3540880674211350,"authorIdStr":"3540880674211350","name":"edward28","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","text":"这篇文章不错，转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/367050139","repostId":2117501807,"repostType":2,"repost":{"id":"2117501807","kind":"news","pubTimestamp":1614878144,"share":"https://www.laohu8.com/m/news/2117501807?lang=&edition=full","pubTime":"2021-03-05 01:15","market":"us","language":"en","title":"Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2117501807","media":"TipRanks","summary":"Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding","content":"<div>\n<p>Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier...</p>\n\n<a href=\"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSorrento Stock Is a Buy Because of Its Strong Drug Pipeline, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier...</p>\n\n<a href=\"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/SIkHKEAXkZblkY98rUX3sw--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/siJU_0HHf5KcEvF65dh0_A--~B/aD00NTE7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/8f3522e85fa7214f56e653c55216edfa","relate_stocks":{"SRNE":"索伦托医疗"},"source_url":"https://finance.yahoo.com/news/protected-sorrento-stock-buy-because-171544278.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2117501807","content_text":"Sorrento (SRNE) has a multi-pronged approach to therapeutics. The company has been constantly adding new options to its bulging pipeline and has made two notable additions over the past month.\nEarlier this week, Sorrento and majority-owned subsidiary Scilex disclosed they are signing an exclusive licensing deal with Aardvark Therapeutics, which will bring ARD-301 under the ever-expanding Sorrento umbrella.\nARD-301, Aardvark’s proprietary LDN (Low Dose Naltrexone) formulation is intended to treat chronic pain, fibromyalgia, and chronic post-COVID syndrome (“long COVID”) and will augment the company’s non-opioid pain franchise.\nScilex plans to kick off a new Phase 2 trial this year for both fibromyalgia and chronic post-COVID syndrome.\nIn previous clinical studies with LDN, the non-opioid, non-addictive therapeutic has displayed activity that has improved a wide array of fibromyalgia symptoms. Right now, for the disorder, there are just 3 FDA approved treatments.\n“With ARD-301, Scilex is adding a key tool to physicians’ therapeutic armamentarium for treating fibromyalgia, a chronic disorder characterized by musculoskeletal pain that affects ~10M U.S. adults,” said B. Riley analyst Mayank Mamtani. \"ARD-301 also serves as a bridge to SRNE's two of three core therapeutic areas (TAs) in non-opioid pain and C-19.”\nThe latest move follows last month’s announcement of another addition; Sorrento is purchasing the outstanding equity of ANP Technologies for a total of $100 million.\nThe acquisition will not only give Sorrento access to a “diverse pipeline” based on ANP’s Nano Intelligent Detection/Delivery System (NIDS®) for the identification of chemical and bio-warfare agents, but adds a second EUA-stage Covid-19 diagnostic to its arsenal.\nMamtani says the acquisition will bring in “extra capacity to produce COVID test kits and provide the know-how to optimize the assay through improving detection capabilities, thereby conferring increased sensitivity and specificity.”\nAll in all, Mamtani keeps a Buy rating on SRNE shares, alongside a $26 price target. The implication for investors? Upside of a hefty 192%. (To watch Mamtani’s track record, click here)\nBig gains are also anticipated by Mamtani’s colleagues. The even higher $28 average price target implies the stock will be changing hands for a 209% premium a year for now. All 4 analysts keeping a tab on Sorrento rate it a Buy, resulting in a Strong Buy consensus rating. (See SRNE stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1636,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}